EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120

Zvavahera Mike Chirenje iD, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C deCamp, Zonglin He, Nicole Grunenberg, Faatima Laher Omar, Kelly E Seaton, Laura Polakowski, Amanda S Woodward Davis, Lucas Maganga und 20 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad434 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Zvavahera Mike Chirenje und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, AIDS Vaccines, HIV Antibodies, HIV Envelope Protein gp120. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, University of Rochester, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults.

Methods

Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses.

Results

We enrolled 160 participants, 55% women, 18–40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups.

Conclusions

The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicAIDS VaccinesHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsOff-Label UseVaccines, CombinedAdolescentAdultFemaleHumansMaleYoung AdultDouble-Blind MethodHIV-1PolysorbatesSqualeneViral VaccinesLipid ASaponins

Stichwörter der Autor:innen

HIVadjuvantdosevaccine

Substanzen

Adjuvants, ImmunologicAIDS VaccinesHIV AntibodiesHIV Envelope Protein gp120PolysorbatesSqualeneViral VaccinesVaccines, CombinedALVAC vaccineMF59 oil emulsion

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, California, USA.
  • Faculty of Medicine and Health Science, University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
  • Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Cape Town HIV Vaccine Trials Network Immunology Laboratory, Cape Town, South Africa.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Centre for Infectious Diseases Research in Zambia, Livingstone, Zambia.

ORCID-Profile: Zvavahera Mike Chirenje, James Kublin

Förderung

  • NIAID NIH HHS
  • University of Rochester
  • Bill and Melinda Gates Foundation
  • NIH HHS
  • National Institute of Allergy and Infectious Disease
  • National Institutes of Health
  • US Public Health Service

Zitieren

APA

Chirenje, Z. M., Laher, F., Dintwe, O., Muyoyeta, M., deCamp, A. C., He, Z., Grunenberg, N., Laher Omar, F., Seaton, K. E., Polakowski, L., Woodward Davis, A. S., Maganga, L., Baden, L. R., Mayer, K., Kalams, S., Keefer, M., Edupuganti, S., Rodriguez, B., Frank, I., …, & McElrath, M. J. (2024). Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad434

Vancouver

Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, et al. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad434

BibTeX
@article{Chirenje2024,
  author = {Chirenje, Zvavahera Mike and Laher, Fatima and Dintwe, One and Muyoyeta, Monde and deCamp, Allan C and He, Zonglin and Grunenberg, Nicole and Laher Omar, Faatima and Seaton, Kelly E and Polakowski, Laura and Woodward Davis, Amanda S and Maganga, Lucas and Baden, Lindsey R and Mayer, Kenneth and Kalams, Spyros and Keefer, Michael and Edupuganti, Srilatha and Rodriguez, Benigno and Frank, Ian and Scott, Hyman and Stranix-Chibanda, Lynda and Gurunathan, Sanjay and Koutsoukos, Marguerite and Van Der Meeren, Olivier and DiazGranados, Carlos A and Paez, Carmen and Andersen-Nissen, Erica and Kublin, James and Corey, Lawrence and Ferrari, Guido and Tomaras, Georgia and McElrath, M Juliana},
  title = {Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad434}
}
Kostenlos starten →